PureTech Health Ownership
| PRTC Stock | USD 18.56 0.54 2.83% |
PureTech |
PureTech Stock Ownership Analysis
The company has price-to-book ratio of 1.41. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. PureTech Health PLC recorded a loss per share of 3.09. The entity had not issued any dividends in recent years. PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. PureTech Health operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 95 people. To find out more about PureTech Health PLC contact the company at 617 482 2333 or learn more at https://www.puretechhealth.com.Besides selling stocks to institutional investors, PureTech Health also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different PureTech Health's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align PureTech Health's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
PureTech Health Quarterly Liabilities And Stockholders Equity |
|
PureTech Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as PureTech Health is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading PureTech Health PLC backward and forwards among themselves. PureTech Health's institutional investor refers to the entity that pools money to purchase PureTech Health's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Pentwater Capital Management Lp | 2024-09-30 | 25 K | Adar1 Capital Management Llc | 2024-09-30 | 3 K | Ubs Group Ag | 2024-09-30 | 647 | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 100.0 | Awm Investment Company Inc | 2024-06-30 | 0.0 | Tower Research Capital Llc | 2024-09-30 | 0.0 | Birch Hill Investment Advisors Llc | 2024-09-30 | 0.0 |
PureTech Health Outstanding Bonds
PureTech Health issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. PureTech Health PLC uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most PureTech bonds can be classified according to their maturity, which is the date when PureTech Health PLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
PureTech Health Corporate Filings
6K | 16th of December 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 7th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 9th of July 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PureTech Health PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PureTech Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puretech Health Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puretech Health Plc Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PureTech Health PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PureTech Health. If investors know PureTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PureTech Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.615 | Earnings Share (3.09) | Revenue Per Share | Quarterly Revenue Growth (0.91) | Return On Assets |
The market value of PureTech Health PLC is measured differently than its book value, which is the value of PureTech that is recorded on the company's balance sheet. Investors also form their own opinion of PureTech Health's value that differs from its market value or its book value, called intrinsic value, which is PureTech Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PureTech Health's market value can be influenced by many factors that don't directly affect PureTech Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PureTech Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if PureTech Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PureTech Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.